Genie Division sale could shore up Scientific Industries amid Bioprocessing losses

Scientific Industries, Inc. (OTCBB: SCND) - Snapshot

What's happening inside the company
Scientific Industries operates two core segments: Benchtop Laboratory Equipment and Bioprocessing Systems. The Benchtop segment is generating positive operating income, while the Bioprocessing segment remains the primary drag on results. Management has been conserving cash via cost reductions, issuing equity (private placements) and liquidating investment securities. After quarter-end the company signed a material asset purchase agreement to sell the Genie Division, which is a potential major liquidity event.

Key points & statistics
- Revenues (Q2 2025): $2,329,900 (down 12.0% YoY from $2,647,300).
- Revenues (6 months 2025): $4,736,400 (down 7.7% YoY from $5,130,800).
- Gross profit (Q2 2025): $1,019,900; gross margin Q2 2025 = 43.8% (vs 48.8% in Q2 2024).
- Net loss (Q2 2025): $(1,522,700); Net loss (6 months 2025): $(3,302,200).
- Loss per share (basic & diluted): Q2 2025 $(0.13); 6 months 2025 $(0.30).
- Segment results Q2 2025: Benchtop operating income $171,400; Bioprocessing operating loss $(1,459,600).
- Cash and cash equivalents (June 30, 2025): $891,400 (up from $587,900 at 12/31/2024).
- Investment securities (June 30, 2025): $390,900 (down from $1,985,000 at 12/31/2024) - significant redemptions provided cash.
- Total assets (June 30, 2025): $10,226,400; Total liabilities: $2,230,700; Shareholders' equity: $7,924,200 (down from $9,119,400 at 12/31/2024).
- Inventories (June 30, 2025): $4,941,100 (up from $4,595,400).
- Operating cash flow (6 months 2025): net cash used in operating activities $(2,762,900).
- Financing activity: April 18, 2025 private placement raised $1,550,000 (net cash provided by financing $1,452,200).
- Customer concentration: one customer accounted for ≥10% of revenue for Q2 and 6 months 2025.
- Subsequent event (Aug 7, 2025): Asset Purchase Agreement to sell substantially all assets of the Genie Division for $9,600,000 (less working capital adjustments) plus earn-out up to $1,500,000; $1,140,000 of earn-out guaranteed under certain conditions.

Positive aspects of the income statement / financial position
- Benchtop Laboratory Equipment is profitable at the operating level (Q2 operating income $171,400; six months $365,500).
- Management reduced G&A (six months G&A down 13.8% YoY to $2,228,200).
- Cash position improved during the period (end cash $891,400) driven by financing and redemptions of investment securities ($1,613,900 redeemed).
- Successful equity raise in April 2025 providing immediate liquidity ($1.55M proceeds).
- Material post-period sale of the Genie Division could generate significant cash (headline $9.6M + earn-out) and change capital structure/liquidity dynamics if completed.

Negative aspects of the income statement / risks
- Revenues declined: Q2 down 12.0% YoY; YTD down 7.7% - demand headwinds cited (global trade tensions, customer delays).
- Profitability pressured: gross margin compressed (Q2 43.8% vs 48.8% prior year) due to higher material/tariff costs and fixed overhead.
- Large and persistent net losses: $(1.52M) in Q2 and $(3.30M) YTD - operating losses driven by Bioprocessing segment.
- Heavy segment losses: Bioprocessing operating loss $(1.46M) in Q2 and $(2.95M) YTD - this is the primary cash and profit drag.
- Operating cash burn: $(2.76M) used in operating activities for six months - ongoing need for financing or asset monetization.
- Equity dilution and expense: stock-based compensation and issuance activity (stock options, warrant modifications) increase potential dilution and non-cash charges (stock comp $375,200 YTD).
- Concentration: reliance on at least one customer >10% of revenue increases exposure to customer-specific risk.
- Full valuation allowance: $12,365,400 valuation allowance on deferred tax assets indicates management does not expect to realize tax benefits from losses.

Bottom line / trader's take
Scientific Industries (OTCBB: SCND) is a small-cap manufacturing group with a profitable Benchtop division offset by a loss-making Bioprocessing unit that has driven overall losses and cash burn. Management has taken sensible steps to preserve liquidity (cost reductions, equity raise, liquidation of investments). The post-period sale of the Genie Division is a material event: if it closes on the disclosed economics it should materially improve liquidity and reduce operating complexity - but it will also remove a portion of recurring revenue and assets. Key watch items for investors: closing of the Troemner transaction, how management redeploys or returns proceeds, pace of Bioprocessing recovery or further divestitures, and quarterly cash burn versus cash generated post-sale.

Data source: Scientific Industries, Inc. Form 10‑Q for quarterly period ended June 30, 2025 (filed August 19, 2025).